EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 42 / No 5 (Mai 2026) Med Sci (Paris), 42 5 (2026) 467-475 References
Issue
Med Sci (Paris)
Volume 42, Number 5, Mai 2026
Agrégation protéique : aux sources des maladies neurodégénératives
Page(s) 467 - 475
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2026065
Published online 29 May 2026
  1. Costes S, Langen R, Gurlo T, et al. beta-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes 2013; 62 : 327–35. [Google Scholar]
  2. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009; 8 : 1150–7. [Google Scholar]
  3. Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ. The association between type 2 diabetes mellitus and Parkinson’s disease. J Parkinsons Dis 2020; 10 : 775–89. [Google Scholar]
  4. De Pablo-Fernandez E, Goldacre R, Pakpoor J, et al. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 2018; 91 : e139–e42. [Google Scholar]
  5. Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 2007; 30 : 842–7. [Google Scholar]
  6. Yue X, Li H, Yan H, et al. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine (Baltimore) 2016; 95 : e3549. [Google Scholar]
  7. Chohan H, Senkevich K, Patel RK, et al. Type 2 diabetes as a determinant of parkinson’s disease risk and progression. Mov Disord 2021; 36 : 1420–9. [Google Scholar]
  8. Cullinane PW, de Pablo Fernandez E, Konig A, et al. Type 2 diabetes and Parkinson’s disease: a focused review of current concepts. Mov Disord 2023; 38 : 162–77. [Google Scholar]
  9. Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10 (suppl 4) : 32–42. [Google Scholar]
  10. Nguyen PH, Ramamoorthy A, Sahoo BR, et al. Amyloid oligomers: a joint experimental/computational perspective on alzheimer’s disease, Parkinson’s disease, type ii diabetes, and amyotrophic lateral sclerosis. Chem Rev 2021; 121 : 2545–647. [Google Scholar]
  11. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012; 33 : 2225–8. [Google Scholar]
  12. Mukherjee A, Morales-Scheihing D, Salvadores N, et al. Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. J Exp Med 2017; 214 : 2591–610. [Google Scholar]
  13. Geng X, Lou H, Wang J, et al. alpha-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am J Physiol Endocrinol Metab 2011; 300 : E276–86. [Google Scholar]
  14. Steneberg P, Bernardo L, Edfalk S, et al. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of alpha-synuclein levels in beta-cells. Diabetes 2013; 62 : 2004–14. [Google Scholar]
  15. Wijesekara N, Ahrens R, Wu L, et al. Alpha-synuclein regulates peripheral insulin secretion and glucose transport. Front Aging Neurosci 2021; 13 : 665348. [Google Scholar]
  16. Sun Y, Guo C, Yuan L, et al. Cynomolgus monkeys with spontaneous type-2-diabetes-mellitus-like pathology develop alpha-synuclein alterations reminiscent of prodromal Parkinson’s disease and related diseases. Front Neurosci 2020; 14 : 63. [Google Scholar]
  17. Martinez-Valbuena I, Amat-Villegas I, Valenti-Azcarate R, et al. Interaction of amyloidogenic proteins in pancreatic beta cells from subjects with synucleinopathies. Acta Neuropathol 2018; 135 : 877–86. [Google Scholar]
  18. Martinez-Valbuena I, Valenti-Azcarate R, Amat-Villegas I, et al. Mixed pathologies in pancreatic beta cells from subjects with neurodegenerative diseases and their interaction with prion protein. Acta Neuropathol Commun 2021; 9 : 64. [Google Scholar]
  19. Mucibabic M, Steneberg P, Lidh E, et al. alpha-Synuclein promotes IAPP fibril formation in vitro and beta-cell amyloid formation in vivo in mice. Sci Rep 2020; 10 : 20438. [Google Scholar]
  20. Wang Y, Bergstrom J, Ingelsson M, Westermark GT. Studies on alpha-synuclein and islet amyloid polypeptide interaction. Front Mol Biosci 2023; 10 : 1080112. [Google Scholar]
  21. Meng L, Li Y, Liu C, et al. Islet amyloid polypeptide triggers alpha-synuclein pathology in Parkinson’s disease. Prog Neurobiol 2023; 226 : 102462. [Google Scholar]
  22. Horvath I, Wittung-Stafshede P. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease. Proc Natl Acad Sci USA 2016; 113 : 12473–7. [Google Scholar]
  23. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998; 19 : 883–9. [Google Scholar]
  24. Rivera JF, Costes S, Gurlo T, et al. Autophagy defends pancreatic beta cells from human islet amyloid polypeptide-induced toxicity. J Clin Invest 2014; 124 : 3489–500. [Google Scholar]
  25. Hou X, Watzlawik JO, Fiesel FC, Springer W. Autophagy in Parkinson’s Disease. J Mol Biol 2020. [Google Scholar]
  26. Rivera JF, Gurlo T, Daval M, et al. Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic beta-cells: protective role of p62-positive cytoplasmic inclusions. Cell Death Differ 2011; 18 : 415–26. [Google Scholar]
  27. Winslow AR, Chen CW, Corrochano S, et al. alpha-Synuclein impairs macroautophagy: implications for Parkinson’s disease. J Cell Biol 2010; 190 : 1023–37. [Google Scholar]
  28. Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 2009; 52 : 1083–6. [Google Scholar]
  29. Costes S, Bertrand G, Ravier MA. Mechanisms of beta-cell apoptosis in type 2 diabetes-prone situations and potential protection by GLP-1-based therapies. Int J Mol Sci 2021; 22. [Google Scholar]
  30. Zeng H, Liu Y, Liu X, et al. Interplay of alpha-synuclein oligomers and endoplasmic reticulum stress in Parkinson’s disease: insights into cellular dysfunctions. Inflammation 2025; 48 : 1590–606. [Google Scholar]
  31. Xxxx S, Ahmad MH, Rani L, Mondal AC. Convergent Molecular pathways in type 2 diabetes mellitus and Parkinson’s disease: insights into mechanisms and pathological consequences. Mol Neurobiol 2022; 59 : 4466–87. [Google Scholar]
  32. Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain 2017; 10 : 53. [Google Scholar]
  33. Zhang P, Zeng L, Gao W, et al. Peroxynitrite scavenger FeTPPS effectively inhibits hIAPP aggregation and protects against amyloid induced cytotoxicity. Int J Biol Macromol 2020; 161 : 336–44. [Google Scholar]
  34. Xu W, Huang Y, Zhou R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell Mol Immunol 2025; 22 : 341–55. [Google Scholar]
  35. Groslambert M, Py BF. NLRP3, un inflammasome sous contrôle. Med Sci (Paris) 2018; 34 : 47–53. [Google Scholar]
  36. Lautier C, Grigorescu F. Maladies neurodégénératives et diabète. Med Sci (Paris) 2009; 25 : 337–40. [Google Scholar]
  37. Chen W, Cai W, Hoover B, Kahn CR. Insulin action in the brain: cell types, circuits, and diseases. Trends Neurosci 2022; 45 : 384–400. [Google Scholar]
  38. Rotermund C, Truckenmuller FM, Schell H, Kahle PJ. Diet-induced obesity accelerates the onset of terminal phenotypes in alpha-synuclein transgenic mice. J Neurochem 2014; 131 : 848–58. [Google Scholar]
  39. Lv YQ, Yuan L, Sun Y, et al. Long-term hyperglycemia aggravates alpha-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model. Transl Neurodegener 2022; 11 : 14. [Google Scholar]
  40. Nowotny K, Jung T, Hohn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5 : 194–222. [Google Scholar]
  41. Hsu YH, Chen YW, Wu MH, Tu LH. Protein glycation by glyoxal promotes amyloid formation by islet amyloid polypeptide. Biophys J 2019; 116 : 2304–13. [Google Scholar]
  42. Abedini A, Cao P, Plesner A, et al. RAGE binds preamyloid IAPP intermediates and mediates pancreatic beta cell proteotoxicity. J Clin Invest 2018; 128 : 682–98. [Google Scholar]
  43. Vicente Miranda H, Szego EM, Oliveira LMA, et al. Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain 2017; 140 : 1399–419. [Google Scholar]
  44. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA 2020; 323 : 548–60. [Google Scholar]
  45. HAS. Haute autorité de santé: Stratégie thérapeutique du patient vivant avec un diabète de type 2. St-Denis : HAS, 2024. [Google Scholar]
  46. Phan F, Bertrand R, Amouyal C, Andreelli F. De la découverte des hormones incrétines aux agonistes doubles et triples du GIP / GLP-1 / glucagon. Med Sci (Paris) 2024; 40 : 837–47. [Google Scholar]
  47. Zaimia N, Obeid J, Varrault A, et al. GLP-1 and GIP receptors signal through distinct beta-arrestin 2-dependent pathways to regulate pancreatic beta cell function. Cell Rep 2023; 42 : 113326. [Google Scholar]
  48. Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 2023; 66 : 1765–79. [Google Scholar]
  49. Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation 2008; 5 : 19. [Google Scholar]
  50. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106 : 1285–90. [Google Scholar]
  51. Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J Neurosci Res 2008; 86 : 326–38. [Google Scholar]
  52. Sun S, Huang L, Jiang G, et al. Neuroprotective effects of lixisenatide against propagation of alpha-synuclein pathology in Parkinson’s disease. Neural Regen Res 2025. [Google Scholar]
  53. Yun SP, Kam TI, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med 2018; 24 : 931–8. [Google Scholar]
  54. Zhang LP, Zhang LY, Li L, Hölscher C. Semaglutide is neuroprotective and reduces α-synuclein levels in the chronic MPTP mouse model of Parkinson’s disease. J Parkinson Dis 2019; 9 : 157–71. [Google Scholar]
  55. Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics. Biochem Pharmacol 2020; 180 : 114187. [Google Scholar]
  56. Wong CK, McLean BA, Baggio LL, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab 2024; 36 : 130–43 e5. [Google Scholar]
  57. Zhang LY, Zhang LP, Li YW, et al. The novel dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson’s disease. J Parkinson Dis 2020; 10 : 523–42. [Google Scholar]
  58. Zhang ZJ, Shi M, Li ZM, et al. A Dual GLP-1/GIP Receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson’s disease. Parkinsons Dis-Us 2023; 2023:7427136 [Google Scholar]
  59. Feng P, Liu Z, Lv D, et al. The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson’s disease. Eur J Pharmacol 2025; 1003 : 177972. [Google Scholar]
  60. Zhang LY, Li C, Zhang ZJ, et al. DA5-CH and semaglutide protect against neurodegeneration and reduce a-synuclein levels in the 6-OHDA Parkinson’s disease rat model. Parkinsons Dis-Us 2022; 2022. [Google Scholar]
  61. Delvadia P, Dhote V, Mandloi AS, et al. Dual GLP-1 and GIP agonist tirzepatide exerted neuroprotective action in a Parkinson’s disease rat model. Acs Chemical Neuroscience 2025; 16 : 818–25. [Google Scholar]
  62. Tian R, Liu K, Lai H, et al. GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson’s disease by promoting mitochondrial homeostasis. Int Immunopharmacol 2025; 165 : 115443. [Google Scholar]
  63. Brauer R, Wei L, Ma T, et al. Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes. Brain 2020; 143 : 3067–76. [Google Scholar]
  64. Gamborg M, Grand MK, Arvedsen J, et al. GLP-1 agonists as potential neuromodulators in development of Parkinson’s disease: a nationwide cohort study. Eur J Neurol 2025; 32 : e70075. [Google Scholar]
  65. Sun M, Wang X, Lu Z, et al. SGLT2 inhibitors vs. metformin for Parkinson’s disease risk reduction in type 2 diabetes. J Parkinsons Dis 2025 ; 15 :1240–1252. [Google Scholar]
  66. Kim HK, Biessels GJ, Yu MH, et al. SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. Neurology 2024; 103 : e209805. [Google Scholar]
  67. Tang H, Lu Y, Okun MS, et al. Glucagon-like peptide-1 receptor agonists and risk of Parkinson’s disease in patients with type 2 diabetes: a population-based cohort study. Mov Disord 2024; 39 : 1960–70. [Google Scholar]
  68. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 2013; 123 : 2730–6. [Google Scholar]
  69. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390 : 1664–75. [Google Scholar]
  70. Vijiaratnam N, Girges C, Auld G, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 2025; 405 : 627–36. [Google Scholar]
  71. McGarry A, Rosanbalm S, Leinonen M, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2024; 23 : 37–45. [Google Scholar]
  72. Meissner WG, Remy P, Giordana C, et al. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med 2024; 390 : 1176–85. [Google Scholar]
  73. Siddeeque N, Hussein MH, Abdelmaksoud A, et al. Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study. Int Immunopharmacol 2024; 143 : 113537. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.